Abstract
Gastro-oesophageal reflux disease, which is experienced daily by a significant proportion of individuals, may result in serious sequelae such as erosive oesophagitis. Short-term treatment with acid antisecretory therapy (a proton pump inhibitor or a histamine H2 receptor antagonist) is highly effective in healing the erosive oesophagitis lesion. However, numerous studies confirm that unless maintenance therapy is initiated virtually all patients will experience oesophagitis relapse within 1 year, as well as an increasing severity of oesophagitis and risk for complications such as Barrett’s oesophagus and adenocarcinoma.
Studies evaluating the efficacy of proton pump inhibitor and H2 antagonist maintenance therapy have found that only the proton pump inhibitors significantly reduce the incidence of oesophagitis relapse. Pharmacoeconomic studies have also confirmed that proton pump inhibitor maintenance therapy is cost effective, by virtue of the ability of these agents to reduce the incidence of relapse as well as prolong the time to relapse and increase the number of weeks per year that patients are without symptoms.
Lansoprazole, a member of the proton pump inhibitor class of agents, has been extensively studied in the treatment of patients with a variety of acid-related disorders. Among those with erosive oesophagitis, maintenance therapy with lansoprazole 15 or 30mg once daily is highly effective in preventing relapse. Studies have documented that lansoprazole 15 and 30mg once daily for six months prevents oesophagitis relapse in up to 81 and 93% of patients, respectively, with comparable percentages of patients remaining in remission after 1 year of treatment. These high rates of remission have also been observed in studies of patients with lesions that were difficult to heal at baseline (resistant to healing with at least 3 months of H2 antagonist therapy). Moreover, lansoprazole produces high remission rates regardless of the grade of erosive oesophagitis before acute healing. Among symptomatic patients with heartburn, lansoprazole provides rapid and effective relief of daytime and night-time heartburn and prevents relapse of symptoms. Lansoprazole has a wide margin of safety and is well tolerated when administered as monotherapy in short-and long-term clinical trials.
Taken together these data suggest that proton pump inhibitor therapy represents the preferred and ideal long-term management strategy for the patient with erosive oesophagitis. Lansoprazole is a well-established member of this class of agents and, as such, has an extensive body of literature that supports its safety, tolerability and clinical efficacy in preventing relapse in these patients.
Similar content being viewed by others
References
Galmich J-P, Bruley des Varannes S. Symptoms and disease severity in gastro-esophageal reflux disease. Scand J Gastroenterol 1994; 29 Suppl. 201: 62–8
Klinkenberg-Knol EC, Feston HPM, Meuwissen SGM. Pharmacological management of gastro-esophageal reflux disease. Drugs 1995; 49: 695–710
Locke GR, Talley NJ, Fett SL, et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterol 1997; 112: 1448–56
Richter JE. Long-term management of gastroesophageal reflux disease and its complications. Am J Gastroenterol 1997; 92(4): 30S–4S
Spechler SJ. Epidemiology and natural history of gastro-oesophageal reflux disease. Digestion 1992; 51 Suppl. 1: 24–9
McDougall NI, Johnston BT, Kee F, et al. Natural history of reflux esophagitis: a 10 year follow up of its effect on patient symptomatology and quality of life. Gut 1996; 38: 481–6
Howden CW, Ballard D, Robieson W. Evidence of therapeutic equivalence of lansoprazole 30 mg and esomeprazole 40 mg in the treatment of erosive oesophagitis. Clin Drug Invest 2002; 22(2): 99–109
Castell DO, Kahrilas PJ, Richter JE, et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 2002; 97: 575–83
Earnest DL, Dorsch E, Jones J, et al. A placebo-controlled dose-ranging study of lansoprazole in the management of reflux esophagitis. Am J Gastroenterol 1998; 93: 238–43
Robinson M, Sahba B, Avner D, et al. A comparison of lansoprazole and ranitidine in the treatment of erosive oesophagitis. Aliment Pharmacol Ther 1995; 9: 25–31
Castell DO, Richter JE, Robinson M, et al. Effacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. The Lansoprazole Group. Am J Gastroenterol 1996; 91: 1749–57
Mulder CJ, Dekker W, Gerretsen M. Lansoprazole 30mg vesus omeprazole 40mg in the treatment of reflux oesophagitis grade II, III, and Iva (a Dutch multicentre trial). Eur J Gastroenterol Hepatol 1996; 8: 1101–6
Sontag SJ, Kogut DG, Fleischmann R, et al. Lansoprazole heals erosive reflux esophagitis resistant to histamine H2-receptor antagonist therapy. Am J Gastroenterol 1997; 92: 429–37
Feldman M, Harford WV, Fisher RS, et al. Treatment of reflux esophagitis resistant to H2-receptor antagonists with lansoprazole, a new H+/K+-ATPase inhibitor: a controlled, double-blind study. Am J Gastroenterol 1993; 88: 1212–7
Richter JE, Kahrilas PJ, Sontag S, et al. Comparing lansoprazole and omeprazole in onset of heartburn relief: results of a randomized, controlled trial in erosive esophagitis patients. Am J Gastroenterol 2001; 96: 3089–98
Mathias SD, Castell DO, Elkin E, et al. Health-related quality of life of patients with acute erosive reflux esophagitis. Dig Dis Sci 1996; 41: 11: 2123–9
Fennerty MB, Castell D, Fendrick AM, et al. The diagnosis and treatment of gastroesophageal reflux disease in a managed care environment: suggested disease management guidelines. Arch Int Med 1996; 156: 477–84
Harris RA, Kuppermann M, Richter JE. Proton pump inhibitors or histamine-2 receptor antagonists for the prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis. Am J Gastroenterol 1997; 92: 2179–87
Hetzel DJ, Dent J, Reed WD, et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 1988; 95: 903–12
Robinson MG, Lanza F, Avner D. Effective maintenance treatment of reflux esophagitis with low-dose lansoprazole: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996; 24: 859–67
Sontag SJ, Kogut DG, Fleischmann R, et al. Lansoprazole prevents recurrence of erosive reflux esophagitis previously resistant to H2-RA therapy. Am J Gastroenterol 1996; 91: 1758–65
Ollyo J-B, Monnier P, Fontolliet C, et al. The natural history, prevalence and incidence of reflux oesophagitis. Gullet 1993; 3 Suppl.: 3–10
Howden CW, Castell DO, Cohen S, et al. The rationale for continuous maintenance treatment of reflux esophagitis. Arch Intern Med 1995; 155: 1465–71
Robinson M, Lanza F, Lansoprazole Study Group. Lansoprazole for one year prevents recurrence of erosive reflux esophagitis [abstract]. Gastroenterology 1994; 106: 166
Sontag SJ, Richter J, Campbell D, et al. Lansoprazole (Lan) for one year prevents recurrence of erosive reflux esophagitis (ERE) [abstract]. Am J Gastroenterol 1993; 88: 1499
Chiba N. Proton pump inhibitors in acute healing and mainteance of erosive or worse esophagitis: a systematic overview. Can J Gastroenterol 1997; 11 Suppl. B: 66B–73B
Gough AL, Long RG, Cooper BT, et al. Lansoprazole versus ranitidine in the maintenance treatment of reflux oesophagitis. Aliment Pharmacol Ther 1996; 10: 529–39
Vigneri S, Termini R, Leandro G, et al. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med 1995; 333: 1106–10
Klinkenberg-Knol EC, Festen HP, Jansen JB, et al. Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med 1994; 121: 161–7
Lundell L, Backman L, Ekstrom P, et al. Prevention of relapse of reflux esophagitis after endoscopic healing: the efficacy and safety of omeprazole compared with ranitidine. Scand J Gastroenterol 1991; 26: 248–56
Fiasse R, Druez P, Coppens JP, et al. Omeprazole in the treatment of patients with severe reflux oesophagitis not responding to H2-receptor antagonists and ineligible for surgery. Acta Gastroenterol Belg 1990; 53: 573–84
Dent J, Yeomans ND, Mackinnon M, et al. Omeprazole versus ranitidine for prevention of relapse in reflux oesophagitis. A controlled double blind trial of their efficacy and safety. Gut 1994; 35: 590–8
Hallerback B, Unge P, Carling L, et al. Omeprazole or ranitidine in long-term treatment of reflux esophagitis: the Scandinavian Clinics for United Research Group. Gastroenterology 1994; 107: 1305–11
Marks RD, Richter JE. Peptic strictures of the esophagus. Am J Gastroenterol 1993; 88: 1160–73
Miller LS, Vinayek R, Frucht H, et al. Reflux esophagitis in patients with Zollinger-Ellison syndrome. Gastroenterology 1990; 98: 341–6
Koop H, Arnold R. Long-term maintenance treatment of reflux esophagitis with omeprazole: prospective study in patients with H2-blocker resistant esophagitis. Dig Dis Sci 1991; 36: 552–7
Carr SJ, Wicks AC. Omeprazole and oesophageal stricture. Lancet 1992; 339: 316
Ching CK, Shaheen MZ, Holmes GKT. Is omeprazole more effective in the treatment of resistant reflux esophagitis and associated peptic stricture?. [abstract]. Gastroenterology 1990; 98: 30
Marks RD, Richter JE, Rizzo J, et al. Omeprazole versus H2-receptor antagonists in treating patients with peptic stricture and esophagitis. Gastroenterology 1994; 106: 907–15
Swarbrick ET, Gough AL, Christian J, et al. Prevention of recurrence of oesophageal stricture, a comparative study of lansoprazole and high dose ranitidine [abstract]. Gastroenterology 1994; 106: 189
Bytzer P, Christensen PB, Damkier P, et al. Adenocarcinoma of the esophagus and Barrett’s esophagus: a population based study. Am J Gastroenterol 1999; 94: 86–91
Devesa SS, Blot WJ, Fraumeni JF. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998; 83: 2050–3
Lagergren J, Bergstrom R, Lindgrena A, et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999; 340: 825–31
Richter JE, Kovacs TOG, Greski-Rose PA, et al. Lansoprazole in the treatment of heartburn in patients without erosive esophagitis. Aliment Pharmacol Ther 1999; 13: 795–804
Howden CW, Henning JM, Huang B, et al. Management of heartburn in a large, randomized, community-based study: comparison for four therapeutic strategies. Am J Gastroenterol 2001; 96: 1704–10
Richter JE, Campbell DR, Kahrilas PJ, et al. Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease. Arch Intern Med 2000; 160: 1803–9
Gore S, Healey CJ, Suton R, et al. Regression of columnar lined (Barrett’s) oesophagus with continuous omeprazole therapy. Aliment Pharmacol Ther 1993; 7: 623–8
Sampliner RE, Romero R, LaFleur L. Effect of up to 3 years of high dose lansoprazole on Barrett’s esophagus. Gastroenterology 1994; 89: 1844–8
Goeree R, O’Brien B, Blackhouse G, et al. Economic evaluation of long term management strategies for erosive esophagitis [abstract]. Annu Meet Int Soc Technol Assess Health Care 1998; 14: 74
Harris RA, Kuppermann M, Richter JE. Prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis of maintenance proton pump inhibition. Am J Med 1997; 102: 78–88
Bate CM, Richardson PDI. A one year model for the cost-effectiveness of treating reflux esophagitis. Br J Med Econ 1992; 2: 5–11
Jonsson B, Stalhammar NO. The cost effectiveness of omeprazole and ranitidine in intermittent and maintenance treatment of reflux esophagitis-the case for Sweden. Br J Med Econ 1993; 6: 111–26
Zagari M, Villa KF, Freston JW. Proton pump inhibitors versus H2 receptor antagonists for treatment of erosive gastroesophageal reflux disease: a cost-comparative study. Am J Manag Care 1995; 1: 247–55
Hatlebakk JG, Berstad A. Lanosprazole 15mg and 30mg daily in maintaining healing and symptom relief in patients with reflux oesophagitis. Aliment Pharmacol Ther 1997; 11: 365–72
Poynard T, Staub JL, Lemerez M, et al. Efficacy and safety of lansoprazole 15mg OAD or 30mg OAD as one year maintenance treatment for erosive reflux esophagitis: a randomized trial [abstract]. Gastroenterology 1995 Apr; 108 (4 Suppl.): A195
Baldi F, Bardhan KD, Borman BC, et al. Lansoprazole maintains healing in patients with reflux esophagitis [abstract]. Gastroenterology 1996 Apr; 110 (4 Suppl.): A55
Carling L, Axelsson C, Forsell H, et al. Lansoprazole versus omeprazole in long term maintenance treatment of reflux oesophagitis: a Scandinavian multicentre trial [abstract 1036]. Gut 1996; 39 Suppl. 3: 182
Hirschowitz BI, Greski-Rose P, Huang B, et al. Lansoprazole is superior to ranitidine in the maintenance of healed erosive esophagitis [abstract]. Gastroenterology 1999; 116: A187
Lauritsen K, Junghard O, Eklund S. Esomeprazole 20 mg compared with lansoprazole 15 mg for maintenance therapy in patients with healed reflux esophagitis. J Gastroenterol Hepatol 2002; 17 Suppl.: A1007
Bell NJV, Burget D, Howden CW, et al. Appropriate acid suppression for management of gastro-oesophageal reflux disease. Digestion 1992; 51 Suppl. 1: 59–67
Lachman L, Howden CW. Twenty-four-hour intragastric pH: tolerance within 5 days of continuous ranitidine administration. Am J Gastroenterol 2000; 95: 57–61
Wilder-Smith CH, Merki HS. Tolerance during dosing with H2-receptor antagonists: an overview. Scand J Gastroenterol 1992; 27 Suppl. 193: 14–9
Sontag SJ. Rolling review: gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1993; 7: 293–312
Feldman M, Burton ME. Histamine-2 receptor antagonists: standard therapy for acid-peptic diseases (second of two parts). N Engl J Med 1990; 323: 1749–55
Koelz HR. Treatment of reflux esophagitis with H2-blockers, antacids and prokinetic drugs: an analysis of randomized clinical trials. Scand J Gastroenterol 1989; 24 Suppl. 156: 25–36
Freston JW, Rose PA, Heller CA, et al. Safety profile of lansoprazole. Drug Saf 1999; 20(2): 195–205
Freston JW. Long-term acid control and proton pump inhibitors: interactions and safety issues in perspective. Am J Gastroenterol 1997; 92(4): 51S–7S
Howden CW, Freston JW. Setting the ‘Gold Standards’ in the management of gastroesophageal reflux disease. Gastroenterol Today 1996; 6: 1–3
Acknowledgements
Dr Freston is a consultant for the following pharmaceutical companies: Johnson and Johnson-Merck; TAP Pharmaceutical Products; Inc.; AstraZeneca; and Pfizer.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Freston, J.W., Jackson, R.L., Huang, B. et al. Lansoprazole for Maintenance of Remission of Erosive Oesophagitis. Drugs 62, 1173–1184 (2002). https://doi.org/10.2165/00003495-200262080-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-200262080-00004